Over the past forty years, the incidence rate and mortality rate of colorectal cancer in China have been increasing, and incidence rate has increased by 2 times than that of the world average。
In the United States, the incidence rate of colorectal cancer has dropped by nearly 40% and the mortality rate has dropped by 51%, depending on early screening for colorectal cancer. Due to the lack of awareness of cancer screening in China, 10% of them are lack of medical care. The mortality rate of colorectal cancer patients in China is twice that of the United States.
The occurrence and development of colorectal cancer is slow and takes more than 10 years. Early detection of colorectal tumors, especially precancerous lesions ( adenomas or advanced adenomas ), is mostly completely curable.Treatment of early intestinal cancer or precancerous lesions is inexpensive, with a five-year survival of more than 94% or even complete cure.
Therefore, colorectal cancer is a completely preventable and treatable type of cancer, and it has important clinical significance to improve the awareness of screening, early detection, early diagnosis and early treatment.
Colonoscopy test compliance is low, colonoscopy doctors are seriously insufficient, medical resources are tight; and patients with contraindications of colonoscopy can not be detected, so colonoscopy is suitable for the diagnosis of colorectal cancer, but not suitable for screening and testing of large-scale population.
The accuracy of fecal occult blood detection is low and the rate of missed detection is high. There is an urgent need for other high-sensitivity detection methods in clinic to detect colorectal cancer earlier and more accurately.
Through extracting and detecting fecal DNA, IColocomf® can be used to find precancerous lesions and early colorectal cancer five years earlier. It can find progressive adenoma with the diameter larger than 1cm, so as to block the cancer in the pre or early stage.
Data source of colonoscopy：Li Cong. Colorectal cancer screening status [J]. Guangdong Medical Journal, 2016 (22).
Data sources of fecal occult blood：Luo Hanqing, Wu Dong, Li Jingnan, et al. Diagnostic value of three consecutive fecal occult blood qualitative tests in colorectal polyps and cancer [J]. Peking Union Medical Journal, 2014 (2): 148-151.
Data source of IColocomf®： As of May 30, 2017, a total of 1563 fecal samples retrieved from 1243 negative, 64 advanced adenomas and 258 colorectal cancer patients were tested to evaluate the diagnostic performance of IColocomf®. The specificity was 94.6% (1176/1243), with the sensitivity to advanced adenoma being 67.2% (43 / 64), and the sensitivity to colorectal cancer being 93.4% (241 / 258) (in press).
Cologuard® Data Source: Exact Sciences Clinical Data.
In 2016, USPSTF in the United States included fecal DNA testing in the screening guidelines; in October 2018, experts consensus on early diagnosis and early screening strategy for colorectal cancer in China recommended fecal DNA testing as a screening test for high-risk groups of colorectal cancer.
The sensitivity and specificity of aichangkang? Are significantly higher than those of other domestic inspection methods, almost comparable to enteroscopy, and higher than those of cologuard? Fecal DNA testing products of the United States.
People between 40 and 74 years old, and those who are unwilling to do colonoscopy, contraindications for colonoscopy, failed bowel preparation or failed colonoscopy.
We believe that the strength is to move the best sincerity of customers